AMA
6.9.2022 08:15:42 CEST | Business Wire | Press release
AMA (ISIN GB00BNKGC5 – ticker ALAMA), a pioneer in Assisted Reality solutions, and moziware, a provider of leading-edge wearable technologies of Industrial Metaverse today announced their global strategic partnership to reshape remote collaboration by combining AMA’s brand new XpertEye On & Live remote assistance solution with moziware’s next-gen cimo smart glasses.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220905005323/en/
Strategic Partnership moziware - AMA
With AMA‘s XpertEye On & Live solution, it only takes just one click on cimo to start collaborating and benefit from full HD video quality with 1080p image resolution, extremely accurate white balance settings, and industrial noise cancellation. Equipped with AMA’s AR-powered remote collaboration solution and the cimo ultra-compact and lightweight smart glasses, frontline workers across manufacturing, audit, telco, healthcare, and other industries can remotely collaborate, complete complex tasks together, and resolve issues smarter, faster, and safer.
“moziware is honored to have AMA as our strategic partner. Through relentless teamwork, we have the latest XpertEye solution seamlessly integrated on cimo with exciting new features like one-button start. We believe the joint solution will revolutionize how frontline workers collaborate and operate in the industrial 4.0 era”, said Dr. Li Bo, CEO of moziware.
“AMA is proud to have teamed up with moziware since 2021 to propose today the latest in voice-activated, hands-free, remote collaboration. Our aggressively priced and easy-to-use solution will help improve safety, efficiency, and productivity of frontline workers around the world", said Christian Guillemot, co-founder and CEO of AMA.
About AMA
With eight years of proven experience in remote assistance solutions, AMA is helping medical institutions and industrial organizations of all sizes accelerate their digital transformation. Our market leading XpertEye Assisted Reality platform has been deployed in more than 100 countries, addressing a wide range of applications like remote diagnostics, inspection, scheduling, and workflow management. These unequaled remote interactive collaboration solutions empower our customers to improve productivity, speed up resolution time, and maximize uptime.
With offices in Europe, in the USA and in the APAC region, AMA can work in every time zone and reach its customers wherever they are.
AMA is listed on Euronext Growth Paris (GB00BNKGZC51 - ALAMA).
More information on www.amaxperteye.com
About mōziware
mōziware is a pioneer in accelerating digital transformation through leading-edge wearable technologies and solutions for the industrial sector and beyond.
Its mission is to create an ecosystem of solutions that leverage Augmented Reality (AR), Artificial Intelligence (AI), and Internet of Things (IoT) technologies to empower executives and frontline workers to make smarter, safer, and faster decisions, resulting in increased productivity, improved safety, optimized workflows, and reduced costs.
For more information, visit: https://moziware.io, contact us at info@moziware.io
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220905005323/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom